Hexbol Plus Tablet contains a combination of Trifluoperazine 5 mg and Trihexyphenidyl 2 mg, formulated to manage symptoms associated with schizophrenia and other psychotic disorders. Trifluoperazine, a typical antipsychotic of the phenothiazine class, exerts its therapeutic effect primarily through dopamine D2 receptor antagonism, thereby reducing hallucinations, delusions, and disorganized thinking. Trihexyphenidyl, an anticholinergic agent, is included to mitigate extrapyramidal side effects such as dystonia, parkinsonism, and akathisia commonly induced by antipsychotic treatment. Hexbol Plus is indicated for patients requiring both antipsychotic therapy and management of drug-induced movement disorders. The combination facilitates improved patient compliance by reducing the pill burden and enhancing symptom control. Dosage should be individualized based on clinical response and tolerability, with careful monitoring for adverse effects including sedation, dry mouth, blurred vision, constipation, and potential anticholinergic toxicity. Caution is advised in patients with glaucoma, cardiovascular disease, or hepatic impairment. Regular follow-up is essential to assess therapeutic efficacy and side effect profile. Hexbol Plus should be used under strict medical supervision, with gradual dose adjustments to optimize treatment outcomes in psychiatric care.